Argyrophilic Nucleolar Organiser Regions in Transitional Cell Bladder Tumours Related to Established Prognostic Factors, Progression and Independent Prognostic Value

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Paraffin-embedded archival biopsy specimens from 229 primary transitional cell carcinomas (TCCs) were stained with silver nitrate to demonstrate the nucleolar organiser regions (Ag-NORs). T3-T4 high grade tumours had higher Ag-NOR counts/nucleus than low grade superficial papillary tumours (p < 0.001). Non-papillary tumours showed more Ag-NORs than papillary ones (p < 0.001). Aneuploid tumours with high S phase fraction had more Ag-NORs than diploid tumours (p < 0.001) and mitotic frequency was also related significantly to Ag-NOR count (p < 0.001). SD of nuclear area and nuclear area as measured by planar morphometry correlated significantly to Ag-NOR count (p < 0.001). Close to 60% of the total number of Ag-NORs/nucleus can be related to other quantitative variables. Ag-NORs predicted independently survival in Ta-Tl tumours (p = 0.016) whereas in the whole series Ag-NORs had no independent prognostic value.

Related collections

Author and article information

Journal

Journal ID (publisher-id): OCL

Journal ID (nlm-ta): Oncology

Journal ID (doi): 10.1159/issn.0030-2414

Title: Oncology

Publisher: S. Karger AG

ISSN (Print): 0030-2414

ISSN (Electronic): 1423-0232

Publication date Subscription-year: 1992

Publication date (Print): 1992

Publication date (Electronic): 26 June 2009

Volume: 49

Issue: 2

Pages: 133-138

Affiliations

^aDepartment of Pathology and ^bDepartment of Surgery, University of Kuopio, Finland

Article

Publisher ID: 227026 Other ID: Oncology 1992;49:133–138

DOI: 10.1159/000227026

PubMed ID: 1574249

SO-VID: dd7e4d70-4f47-4aeb-b224-46a2ebe46144

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Call for Papers: Beyond Biology: The Crucial Role of Sex and Gender in Oncology

Submit here before July 31, 2024

Argyrophilic Nucleolar Organiser Regions in Transitional Cell Bladder Tumours Related to Established Prognostic Factors, Progression and Independent Prognostic Value

Read this article at

Abstract

Related collections

Karger: Oncology

Author and article information

Journal

Affiliations

Article

History

Page count

Categories

Comments

Comment on this article

Similar content 236